A Phase 3 interventional study of avatrombopag (lower baseline platelet count) and placebo (lower baseline platelet count) in Thrombocytopenia Associated With Liver Disease, sponsored by Eisai Inc.. Completed at 122 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-27.
Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.
Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 4th largest by enrollment, is one of 2 that started in 2013, is one of 5 in phase 3, and was the 3rd registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Peking University People's Hospital · Sites in China
Ages 18–65
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
University of Virginia · Sites in United States
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 6 · Phase 4 4
First in 2009; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 50 across the 23 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 6 studies filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing avatrombopag in Thrombocytopenia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease. The study will evaluate avatrombopag in the treatment of thrombocytopenia associated with liver disease prior to an elective procedure to reduce the need for platelet transfusions or any rescue procedure for bleeding due to procedural and post-procedural bleeding complications. Participants will be enrolled into 2 cohorts according to mean baseline platelet count and, within each baseline platelet count cohort will be further stratified by risk of bleeding associated with the elective procedure (low, moderate, or high) and hepatocellular carcinoma (HCC) status (Yes or No).
This study will consist of 3 phases: Prerandomization, Randomization, and a Follow-up Phase. The Prerandomization Phase includes one Screening Visit that will take place from Day -14 through Day -1; the Randomization Phase includes the Baseline Period, Treatment Period, and Procedure Day Period (5 to 8 days after last dose of study drug [Study Day 10 to 13]). The Follow-up Phase comprises 2 visits: 7 days post Procedure Day and 30 days after receiving the last dose of study drug. Permitted procedures include: Paracentesis; Thoracentesis; Gastrointestinal endoscopy with or without plans for biopsy, colonoscopy, polypectomy, or variceal banding; Liver biopsy; Bronchoscopy with or without plans for biopsy; Ethanol ablation therapy or chemoembolization for HCC; Vascular catheterization (including right side procedures in participants with pulmonary hypertension); Transjugular intrahepatic portosystemic shunt; Dental procedures; Renal biopsy; Biliary interventions; Nephrostomy tube placement; Radiofrequency ablation; and Laparoscopic interventions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
Drug: avatrombopag (lower baseline platelet count)
placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
Drug: placebo (lower baseline platelet count)
40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
Drug: avatrombopag (higher baseline platelet count)
placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
Drug: placebo (higher baseline platelet count)
60 mg avatrombopag (3 x 20 mg tablets)
60 mg placebo (3 x 20 mg matching placebo tablets)
40 mg avatrombopag (2 x 20 mg tablets)
40 mg placebo (2 x 20 mg matching placebo tablets)
Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure
Responders were defined as participants who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following a scheduled procedure. Participants with missing information due to early withdrawal or other reasons were conservatively considered as having received a transfusion in the analysis, (i.e. a Non-responder).
Time frame: Randomization (Visit 2), up to 7 Days following a scheduled procedure
Percentage of Participants Who Achieved a Platelet Count Greater Than or Equal to 50 x 10^9/L on Scheduled Procedure Day
Responders were defined as participants who achieved a platelet count greater than or equal to 50 x 10\^9/L on the procedure day. Participants missing a platelet count on the procedure day were conservatively considered as not achieving a platelet count of 50x10\^9/L in the analysis, (i.e. Non-responders).
Time frame: Day 10 to Day 13 (Visit 4)
Change From Baseline in Platelet Counts on Scheduled Procedure Day
Last observation carried forward was used for participants with a missing platelet count on the scheduled procedure day. Platelet count was measured preprocedure and before any platelet transfusion.
Time frame: Baseline (Visit 2) to Procedure Day 10 to Day 13 (Visit 4)
Percentage of Participants With a World Health Organization (WHO) Bleeding Score Greater Than or Equal to 2 After Randomization and up to 7 Days After an Scheduled Procedure
The severity of bleeding events was assessed by the investigator (or appropriately delegated study site personnel) using the WHO bleeding scale. The WHO bleeding scale is a clinical investigator-assessed five-point scale with Grade 0 = No bleeding, Grade 1 = Petechial bleeding, Grade 2 = Mild blood loss (clinically significant), Grade 3 = Gross blood loss requires transfusion (severe), and Grade 4 = Debilitating blood loss, retinal or cerebral associated with fatality. Participants with missing information are considered as having a WHO bleeding score greater than or equal to 2 in the analysis.
Time frame: Baseline (Visit 2) up to 7 days post scheduled procedure
Number of Participants Experiencing an Adverse Event
Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events, including platelet transfusion-related complications; routine laboratory evaluation for hematology, serum chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); the performance of physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. Treatment-emergent adverse events (TEAEs) were defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. Treatment-related AEs were considered by the investigator to be possibly or probably related to study drug.
Time frame: From date of first dose of study drug up to 30 days after the last dose of study drug, up to approximately 3 years and 2 months
| Milestone | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) |
|---|---|---|---|---|
| Started | 43 | 70 | 33 | 58 |
| Completed | 37 | 68 | 31 | 55 |
| Not completed | 6 | 2 | 2 | 3 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 | 1 | 1 |
| Withdrew: Subject choice | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 0 |
Responders were defined as participants who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following a scheduled procedure. Participants with missing information due to early withdrawal or other reasons were conservatively considered as having received a transfusion in the analysis, (i.e. a Non-responder).
| Percentage of participants | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) |
|---|---|---|---|---|
| Percentage of Participants Who Did Not Require a Platelet Transfusion After Randomization and up to 7 Days Following a Scheduled Procedure | 34.9 (20.6 to 49.1) | 68.6 (57.7 to 79.4) | 33.3 (17.2 to 49.4) | 87.9 (79.5 to 96.3) |
Responders were defined as participants who achieved a platelet count greater than or equal to 50 x 10\^9/L on the procedure day. Participants missing a platelet count on the procedure day were conservatively considered as not achieving a platelet count of 50x10\^9/L in the analysis, (i.e. Non-responders).
| Percentage of participants | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) |
|---|---|---|---|---|
| Percentage of Participants Who Achieved a Platelet Count Greater Than or Equal to 50 x 10^9/L on Scheduled Procedure Day | 7.0 (0.0 to 14.6) | 67.1 (56.1 to 78.1) | 39.4 (22.7 to 56.1) | 93.1 (86.6 to 99.6) |
Last observation carried forward was used for participants with a missing platelet count on the scheduled procedure day. Platelet count was measured preprocedure and before any platelet transfusion.
| platelet count x 10^9 per liter | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) |
|---|---|---|---|---|
| Change From Baseline in Platelet Counts on Scheduled Procedure Day | 3.0 ± 10.01 | 31.3 ± 24.9 | 5.9 ± 14.89 | 44.9 ± 32.96 |
The severity of bleeding events was assessed by the investigator (or appropriately delegated study site personnel) using the WHO bleeding scale. The WHO bleeding scale is a clinical investigator-assessed five-point scale with Grade 0 = No bleeding, Grade 1 = Petechial bleeding, Grade 2 = Mild blood loss (clinically significant), Grade 3 = Gross blood loss requires transfusion (severe), and Grade 4 = Debilitating blood loss, retinal or cerebral associated with fatality. Participants with missing information are considered as having a WHO bleeding score greater than or equal to 2 in the analysis.
| Percentage of participants | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) |
|---|---|---|---|---|
| Percentage of Participants With a World Health Organization (WHO) Bleeding Score Greater Than or Equal to 2 After Randomization and up to 7 Days After an Scheduled Procedure | 0.0 | 1.4 | 6.1 | 1.7 |
Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events, including platelet transfusion-related complications; routine laboratory evaluation for hematology, serum chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); the performance of physical examinations; and Doppler sonography. AE severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death related to the AE. All AEs graded as 4 or 5 were considered to be serious. Treatment-emergent adverse events (TEAEs) were defined as an AE that started on or after the date of first dose of study drug, up to 30 days after the last dose of study drug. Treatment-related AEs were considered by the investigator to be possibly or probably related to study drug.
| Participants | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) |
|---|---|---|---|---|
| TEAEs | 22 | 36 | 15 | 28 |
| Treatment-related TEAEs | 9 | 6 | 2 | 4 |
| Serious TEAEs | 1 | 1 | 1 | 1 |
| TEAEs leading to study drug dose adjustment | 0 | 0 | 0 | 0 |
| TEAEs leading to study drug withdrawal | 0 | 0 | 0 | 0 |
| TEAEs leading to study drug dose reduction | 0 | 0 | 0 | 0 |
| TEAEs leading to study drug dose interruption | 0 | 0 | 0 | 0 |
Collected over From date of first dose of study drug up to 30 days after the last dose of study drug, up to approximately 3 years and 2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 60 mg Placebo (Lower Baseline Platelet Count) | 0/43 (0%) | 1/43 (2.3%) | 22/43 (51.2%) |
| 60 mg Avatrombopag (Lower Baseline Platelet Count) | 0/70 (0%) | 1/70 (1.4%) | 30/70 (42.9%) |
| 40 mg Placebo (Higher Baseline Platelet Count) | 1/33 (3%) | 1/33 (3%) | 15/33 (45.5%) |
| 40 mg Avatrombopag (Higher Baseline Platelet Count) | 0/57 (0%) | 1/57 (1.8%) | 14/57 (24.6%) |
| Event | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/43 | 0/70 | 1/33 | 0/57 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/43 | 0/70 | 1/33 | 0/57 |
| Hepatic encephalopathyNervous system disorders | 1/43 | 0/70 | 0/33 | 0/57 |
| Ileus paralyticGastrointestinal disorders | 0/43 | 0/70 | 0/33 | 1/57 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/43 | 0/70 | 0/33 | 1/57 |
| HaematemesisGastrointestinal disorders | 0/43 | 1/70 | 0/33 | 0/57 |
| Event | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 2/43 | 11/70 | 4/33 | 4/57 |
| Abdominal pain upperGastrointestinal disorders | 5/43 | 2/70 | 3/33 | 1/57 |
| NauseaGastrointestinal disorders | 5/43 | 6/70 | 2/33 | 3/57 |
| HeadacheNervous system disorders | 4/43 | 2/70 | 1/33 | 2/57 |
| Puncture site haemorrhageGeneral disorders | 0/43 | 0/70 | 3/33 | 0/57 |
| Abdominal painGastrointestinal disorders | 3/43 | 2/70 | 1/33 | 2/57 |
| DiarrhoeaGastrointestinal disorders | 3/43 | 3/70 | 0/33 | 2/57 |
| FatigueGeneral disorders | 3/43 | 1/70 | 0/33 | 2/57 |
| DizzinessNervous system disorders | 3/43 | 3/70 | 1/33 | 0/57 |
| Transfusion reactionInjury, poisoning and procedural complications | 1/43 | 0/70 | 2/33 | 0/57 |
Full Analysis Set (FAS) was defined as the group of all randomized participants.
| Age, Continuous(years) | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) | Total |
|---|---|---|---|---|---|
| Mean | 57.3 ± 11.98 | 58.6 ± 14.18 | 59.2 ± 10.31 | 57.9 ± 11.11 | 58.2 ± 12.24 |
| Sex: Female, Male(Participants) | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) | Total |
|---|---|---|---|---|---|
| Female | 16 | 20 | 16 | 25 | 77 |
| Male | 27 | 50 | 17 | 33 | 127 |
| Ethnicity (NIH/OMB)(Participants) | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 12 | 11 | 7 | 15 | 45 |
| Not Hispanic or Latino | 29 | 56 | 25 | 42 | 152 |
| Unknown or Not Reported | 2 | 3 | 1 | 1 | 7 |
| Race (NIH/OMB)(Participants) | 60 mg Placebo (Lower Baseline Platelet Count) | 60 mg Avatrombopag (Lower Baseline Platelet Count) | 40 mg Placebo (Higher Baseline Platelet Count) | 40 mg Avatrombopag (Higher Baseline Platelet Count) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 10 | 25 | 8 | 12 | 55 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 0 | 2 | 6 |
| White | 27 | 40 | 24 | 40 | 131 |
| More than one race | 4 | 3 | 0 | 4 | 11 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
Showing the first 100 of 122 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2013 to primary completion in Jan 2017, 38 months.
Results were first posted in Feb 2018, 1 year after primary completion.
Of 29 phase 3 interventional studies under Thrombocytopenia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 45. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag